Trial: 201901148

A phase II study of inotuzumab ozogamicin followed by blinatumomab for Ph-negative, CD22-positive B-lineage acute lymphoblastic leukemia in newly diagnosed older adults or adults with relapsed or refractory disease

Phase

II

Principal Investigator

Uy, Geoffrey

Disease Site

Acute Lymphocytic Leukemia (ALL); Lymphoid Leukemia

Learn more about this study at: clinicaltrials.gov